Why the camizestrant EU assessment left out the patient-reported outcome results—and what this means for patient-centered evidence

Since January 2025, certain medicinal products—those with a new active substance for the treatment of cancer and advanced therapy medicinal products—have been subject to joint clinical assessment (JCA) at EU level. The aim is to provide a single EU-level assessment of their clinical evidence and reduce duplication across Member States. JCAs support national health technology assessment (HTA) processes by analyzing the relative effects of a health technology on health outcomes.
The EU JCA of camizestrant (Etcamah), endorsed in August 2026, provides an instructive case study in the challenges of generating patient-centered evidence that is both relevant to patients and interpretable for HTA.
SERENA-6 enrolled patients with ER-positive, HER2-negative advanced breast cancer who had received at least six months of first-line aromatase inhibitor plus CDK4/6 inhibitor without disease progression and monitored them for ESR1 mutations using ctDNA testing every two to three months. Patients with a detected mutation and no progression were randomized to switch to camizestrant or continue their aromatase inhibitor, in both cases continuing the CDK4/6 inhibitor (JCA, pp. 35–36). The trial included patient-reported outcome (PRO) measures assessing breast cancer–specific symptoms and health-related quality of life (HRQoL). Patients were also consulted during the JCA. Yet the assessors did not include the submitted PRO results in the assessment report, citing missing data, methodological limitations and inappropriate analytical approaches (pp. 73–74).
1. Missing data undermined the PRO evidence
SERENA-6 assessed the EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5L and EQ-VAS, with electronic assessments at baseline, every four weeks for the first 12 weeks and every eight weeks thereafter until second progression, alongside specified discontinuation assessments (pp. 55–56).
However, the assessors identified substantial baseline missingness, general attrition and differential informative attrition. Around one third of patients had no baseline PRO assessment, and by week 76 usable data were available for only 7–8% of patients in the control arm. These problems undermined the interpretation of both change-from-baseline and time-to-deterioration (TTD) analyses (pp. 61–62, 73–74).
2. Meaningful change thresholds were closely scrutinized
The JCA examined the within-patient meaningful change thresholds used for the EORTC measures. Anchors included the Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS) and EORTC QLQ-C30 Item 29. Distribution-based methods were used to triangulate where suitable anchors were unavailable or inadequate.
Although the general approach was viewed as broadly consistent with SISAQOL-IMI recommendations, the assessors raised questions about deriving thresholds after data collection began, the reporting of blinding, the acceptability of particular thresholds and the absence of sensitivity analyses exploring alternatives (p. 60).
3. Time to deterioration may miss the patient journey
The assessors questioned the suitability of TTD analyses for continuous longitudinal HRQoL outcomes, noting that they may not capture longer-term trajectories. PRO collection also stopped at second progression, even though the analyses followed a treatment-policy approach in which the whole patient trajectory is relevant (p. 61). They further highlighted that more patients in the camizestrant group received subsequent chemotherapy, whose HRQoL implications could not be reliably assessed from the available analyses (pp. 73–74).
4. Patients identified experiences that questionnaires may miss
Patient contributors raised practical and emotional aspects of treatment: hospital visits, tablet burden, treatment convenience, repeated ESR1 testing, waiting for results and anxiety. One contributor questioned whether standard HRQoL questionnaires fully reflected lived experience (pp. 85, 95).
A patient commenting on the draft JCA also emphasized persistent endocrine-treatment effects and the consequences of adverse events for daily activities, independence, work and social life (p. 95).
5. Patient relevance and methodological acceptability are different questions
The same patient argued that PROs, symptom control and HRQoL were among the most important outcomes for endocrine therapy assessment, and called for a summary of the available findings, with a transparent account of their weaknesses, even when methodological limitations prevented their inclusion in the main analysis (p. 95).
The JCA illustrates an important tension: outcomes can be highly relevant to patients while the evidence available to assess them is too uncertain to support reliable conclusions.
What does this mean for evidence generation?
These observations show why patient-centered evidence needs to be both relevant and interpretable. Trial teams need to consider whether the measures reflect outcomes patients prioritize, whether data collection can support credible longitudinal analyses, and whether meaningful change thresholds are defined and reported transparently. The estimand should also explain how intercurrent events, such as subsequent therapy, and missing data will be handled.
Patient consultation can identify what matters to patients. In-trial interviews can add a systematically collected account of how participants experience treatment, clarify concepts that questionnaires may not capture and help interpret the context behind reported changes. They cannot recover missing PRO assessments or establish comparative treatment effects. Their contribution depends on the evidence question and how they are integrated with the trial's other data.
Looking beyond the JCA: what does our own research tell us?
The challenges highlighted in the camizestrant JCA reflect a broader question we have been exploring at CLINIGMA: how can patient experience evidence be designed and presented so that it makes a meaningful contribution to HTA decision-making?
To investigate this, we recently undertook a targeted review of HTA guidance and published appraisal cases in collaboration with HTA experts at Fingerpost Consulting, examining how qualitative patient evidence is recognized, evaluated and used by HTA bodies.
Our findings suggest that, although qualitative evidence is increasingly recognized within HTA guidance, how it is applied in practice is less apparent. Importantly, the examples we identified suggest that qualitative evidence is most likely to contribute when it addresses a specific appraisal question, such as interpreting a clinical endpoint or informing an economic model, rather than providing general contextual information about the patient experience.
Building on this work and our recent discussion paper on in-trial patient evidence in HTA, we will be sharing a practical framework for developing JCA-ready patient experience evidence strategies in the coming months, focusing on how to identify evidence needs early, select appropriate methods and plan for the requirements of HTA assessment. Our aim is to help move patient experience evidence beyond collection towards more purposeful generation and use in decision-making.
Sources
- Member State Coordination Group on Health Technology Assessment. Joint Clinical Assessment Report of Camizestrant (Etcamah), Version 1.0 (JCA-MP-2024-14). Endorsed 19 August 2026.
- Fingerpost Consulting and CLINIGMA. Influence of qualitative research methods on reimbursement and payer decision making – Desk Research. Unpublished report, 7 October 2026.
- CLINIGMA. Qualitative In-Trial Patient Evidence in HTA: How in-trial interview experience evidence could contribute more directly to health technology assessment. Unpublished discussion paper, October 2026.








.png)